Anteris Technologies Global Corp. (AVR)·Q1 2025 Earnings Summary

Executive Summary

• Q1 2025 delivered operational progress (IDE submitted for PARADIGM pivotal trial; manufacturing capacity scaled) alongside expected development-stage financials: net sales $0.556m and diluted loss per share of $0.61; R&D investment increased to support trial readiness .
• Revenue beat consensus while EPS modestly missed: revenue $0.556m vs $0.346m consensus; EPS -$0.589 vs -$0.542 consensus; one EPS estimate and four revenue estimates underpin consensus. Bold beat on revenue reflects tissue sales mix; EPS miss reflects higher R&D and FX headwinds [GetEstimates].
• Guidance was operational, not financial: trial start targeted for Q3 2025 pending IDE approval; manufacturing capacity targeting ≥3x 2024 levels; ADAPT tissue dual-sourcing to mitigate supply risk .
• Strategic milestones: 100 patients treated with DurAVR THV; one-year outcomes show sustained favorable hemodynamics and safety; inclusion in Russell 2000 index raises profile and liquidity .
• Near-term stock reaction catalysts: FDA IDE approval timing and pivotal trial initiation, continued clinical data flow, and manufacturing readiness updates—key de-risking events for the medium-term thesis .

What Went Well and What Went Wrong

• What Went Well

  • IDE for PARADIGM pivotal trial submitted; company “on track to commence… in the third quarter of 2025” pending FDA approval .
  • Clinical milestone: 100 patients treated; one-year data showed EOA 2.1±0.2 cm², MPG 8.6±2.6 mmHg, DVI 0.58, with no cardiovascular/valve-related mortality and no PPM in small annuli—differentiated hemodynamics vs current devices .
  • Manufacturing scale-out to new ISO clean rooms targeting ≥3x 2024 capacity; ADAPT tissue dual-sourced (US and Australia) to mitigate supply chain risks .

• What Went Wrong

  • Net sales fell 27% YoY to $0.556m as tissue product demand declined; LeMaitre transition agreement expired in January 2025, reducing expected tissue revenue contribution .
  • R&D expenses rose 42% YoY to $16.5m on manufacturing scale-up and trial prep; SG&A decreased YoY but legal/tax/compliance increased amid dual listing and operational matters .
  • FX moved from a $1.233m gain in Q1 2024 to a $0.219m loss in Q1 2025, reflecting USD depreciation vs AUD; this pressured EPS alongside higher operating spend .

Financial Results

Values with asterisks were retrieved from S&P Global.*

Consensus vs Reported (Q1 2025):

Source: S&P Global consensus (Primary EPS Consensus Mean, Revenue Consensus Mean; # of Estimates: EPS=1, Revenue=4) [GetEstimates].

Geographic Revenue (Q1 2025):

KPIs and Operating Drivers:

Trend (Prior Two Quarters):

Values with asterisks were retrieved from S&P Global.*

Guidance Changes

Earnings Call Themes & Trends

Note: No Q1 2025 earnings call transcript was found; themes reflect ASX/press releases and 10‑Q.

Items marked with * reflect S&P Global trend context where document detail for Q3 2024 was limited.

Management Commentary

• “Our focus this quarter has been on completing the substantial technical, clinical and regulatory work required to lodge our IDE application, which was successfully submitted during the period… we continue to scale our field based Clinical Team, Manufacturing and Quality organizations to ensure we are able to meet the demands of the PARADIGM Trial” — Wayne Paterson, Vice Chairman & CEO .
• Company reiterated readiness actions: clinical specialist expansion, CRO engagement across U.S., Canada, Europe to accelerate enrollment post-IDE approval .
• One-year DurAVR THV data highlighted sustained hemodynamics and safety, including no PPM in small annuli vs commercial devices’ 11.2–35.3% PPM range (SMART study reference) .

Q&A Highlights

• No Q1 2025 earnings call transcript identified; no Q&A available to assess analyst focus or management clarifications [List: earnings-call-transcript returned none].
• Key areas likely to be probed when available: IDE review timelines, pivotal trial enrollment pace/site readiness, manufacturing scale ramp profile, capital plan and runway under going-concern disclosures .

Estimates Context

• Q1 2025 revenue beat consensus ($0.556m vs $0.346m), reflecting continued tissue sales amid transition away from LeMaitre and variable demand; EPS missed modestly (-$0.589 vs -$0.542) given stepped-up R&D, FX losses, and higher compliance costs [GetEstimates] .
• Estimate density was light (EPS: 1 estimate; Revenue: 4 estimates), suggesting limited Street coverage and higher revision sensitivity post-report [GetEstimates].
• Forward estimates likely to adjust to: lower near-term tissue revenue contributions, elevated R&D through trial start, and liquidity plans; operational milestones (IDE approval, trial start) can prompt reassessment of commercialization timelines .

Key Takeaways for Investors

• Revenue outperformed consensus; EPS lagged modestly—consistent with a development-stage profile prioritizing clinical/regulatory progress over near-term profitability [GetEstimates] .
• Regulatory de-risking: IDE submission achieved; trial start targeted Q3 2025, pending FDA approval—material catalysts that can re-rate execution risk .
• Clinical differentiation: favorable one-year hemodynamics and safety (no PPM in small annuli) underscore potential competitive advantage vs current THV devices .
• Operational readiness: ≥3x manufacturing capacity and dual-source ADAPT tissue reduce execution and supply risk as pivotal trial begins .
• Revenue mix in transition: expect continued softness in tissue sales post-LeMaitre agreement expiration; investors should focus on trial progress rather than near-term revenue growth .
• Liquidity and going concern: $49.0m cash with stated need for additional capital; anticipate financing activity ahead of pivotal trial ramp .
• Trading implications: stock likely sensitive to FDA IDE decision and site/enrollment updates; any delays to Q3 start or negative clinical signals would be high-impact; conversely, on-time trial initiation and continued favorable data are positive catalysts .

---

Primary sources read in full:

• Q1 2025 Form 8‑K Item 2.02 with ASX Quarterly Results Announcement and First Quarter 2025 press release .
• Q1 2025 Form 10‑Q including financial statements, MD&A, liquidity and risk disclosures .
• Prior-period context: FY 2024 results 8‑K and ASX announcements (LeMaitre transition, cash balance, EU‑EFS) .

S&P Global notes: Values marked with asterisks in tables were retrieved from S&P Global. Consensus tables derive from S&P Global estimates.